This is the first part of a 4-part podcast series featuring Cédric Guiard, CEO of Cydolia, and Hugo Le Calvez, CMO of Cydolia. You can watch the full podcast here.
Hugo Le Calvez (CMO, Cydolia):
One of the most frequent questions we receive is, “Why do major brands like Lancôme and Biotherm use Cydolia for their clinical studies?” A lot of this curiosity revolves around the speed and efficiency of our 3D efficacy studies compared to traditional clinical trials. One specific question we hear is, “How is it faster to conduct a 3D efficacy study than a traditional clinical study?” Could you walk us through the differences?
Why are 3D clinical trials faster?
Cédric Guiard (CEO, Cydolia):
Traditional efficacy studies rely on multiple devices to measure specific parameters, like skin texture or moisture levels, at selected points on the face. Each device is typically limited to capturing one or two parameters at a time.
In contrast, our 3D photometric technology measures all physical properties of the face in just 7 to 10 seconds. This includes relied, global and detailed morphology, optical properties, and even mechanical properties.
Concrete benefits of 3d technology
Hugo: That sounds impressive. Could you give us a concrete example to help our audience understand how much faster this process really is?
Cédric: Of course. Let’s take a typical clinical study for product claims. Traditionally, you might test 100 volunteers, with clinics measuring different parameters over the course of about a month. With our 3D photometric technology, we can perform the same measurements for the same number of participants in just 3 to 4 days.
Why leading brands trust Cydolia
Hugo: That’s an incredible difference. It’s no wonder that brands like Lancôme and Biotherm choose Cydolia. Could you elaborate on what sets your technology apart?
Cédric: Our system is both faster and more comprehensive. Because it captures detailed data for the entire face in seconds, we eliminate the inconcistencies of traditional methods. This not only saves time but also provides a more accurate and holistic view of the product’s efficacy.
Expanding the Reach of 3D Clinical Trials
Hugo: It’s clear that Cydolia’s approach is revolutionizing cosmetics testing. Do you see this technology expanding beyond cosmetics?
Cédric: Absolutely. While we’re focused on cosmetics and dermatology right now, the same technology has enormous potential in aesthetic medicine. The ability to measure detailed skin properties quickly and accurately opens up new possibilities for innovation across industries.
Conclusion
Hugo: Thank you, Cédric, for explaining how 3D clinical trials are changing the game for efficacy studies. It’s exciting to see how this technology is helping brands innovate faster and more efficiently.
Cédric: My pleasure, Hugo. At Cydolia, our mission is to provide brands with the tools they need to succeed in a competitive market, and I’m thrilled to see the positive impact this is having.
Hugo: Thank you to everyone who tuned in today. If you have more questions about Cydolia’s 3D clinical trials, feel free to reach out. Stay innovative!
